Dehm, Scott M.

Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance

Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 834

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., et al. (2018) · Cell

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 733

Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing

Viswanathan, S. R., Ha, G., Hoff, A. M., Wala, J. A., Carrot-Zhang, J., Whelan, C. W., Haradhvala, N. J., Freeman, S. S., Reed, S. C., Rhoades, J., et al. (2018) · Cell

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 365

Molecular regulation of androgen action in prostate cancer.

Dehm, S. M., & Tindall, D. J. (2006) · Journal of Cellular Biochemistry

Prostate Cancer Treatment and ResearchSperm and Testicular Function

Cited by 336

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer

Henzler, C., Li, Y., Yang, R., McBride, T., Ho, Y., Sprenger, C., Liu, G., Coleman, I., Lakely, B., Li, R., et al. (2016) · Nature Communications

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 173

p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.

Debes, J. D., Comuzzi, B., Schmidt, L. J., Dehm, S. M., Culig, Z., & Tindall, D. J. (2005) · Cancer Research

Prostate Cancer Treatment and ResearchEstrogen and related hormone effects

Cited by 92

Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion-independent prostate cancer cells.

Dehm, S. M., Regan, K. M., Schmidt, L. J., & Tindall, D. J. (2007) · Cancer Research

Prostate Cancer Treatment and ResearchEstrogen and related hormone effects

Cited by 84

Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes

Hwang, J., Likasitwatanakul, P., Deshmukh, S. K., Wu, S., Kwon, J. J., Toye, E., Moline, D., Evans, M. G., Elliott, A., Passow, R., et al. (2025) · Clinical Cancer Research

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 12

1406P Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)

Lang, J., Tagawa, S. T., Slovin, S., Emamekhoo, H., Rathkopf, D., Abida, W., Autio, K., Xiao, H., Molina, A. M., Eickhoff, J., et al. (2022) · Annals of Oncology

Prostate Cancer Treatment and ResearchLung Cancer Treatments and Mutations

Cited by 9